Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Engene Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are assigned to 3 distinct examiners, which means each matter is being reviewed by a different person. The data also shows 3 distinct art units are involved, indicating that the technical subject matter of each action falls under a different administrative section of the patent office. This distribution across 3 distinct examiners and 3 distinct art units means there is no overlap in the current prosecution of these 3 pending office actions.
The busiest examiner is BURKHART, MICHAEL D, who is responsible for 1 busiest examiner pending office action. This 1 busiest examiner pending office action represents a portion of the 3 pending office actions total. Since there are 3 distinct examiners for 3 actions, the workload is not concentrated. The involvement of 3 distinct art units requires the applicant to address the standards of multiple technical divisions. The 1 busiest examiner pending office action for BURKHART, MICHAEL D is the same as the workload for the other examiners in the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKHART, MICHAEL D | 1 | 62.4% | +11.8% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 63.9% | +18.1% |
| ROGERS, JAMES WILLIAM | 1 | 46.1% | +22.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18821962 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | BURKHART, MICHAEL D | — |
| 17438921 | REVERSIBLE COATING OF CHITOSAN-NUCLEIC ACID NANOPARTICLES AND METHODS OF THEIR USE | ROGERS, JAMES WILLIAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18821962 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | BURKHART, MICHAEL D | — |
| 18277944 | COMBINATION GENE THERAPY FOR TREATMENT OF METASTATIC CANCER | POLIAKOVA-GEORGAN, EKATERINA | — |
| 17438921 | REVERSIBLE COATING OF CHITOSAN-NUCLEIC ACID NANOPARTICLES AND METHODS OF THEIR USE | ROGERS, JAMES WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1637 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18821962 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | BURKHART, MICHAEL D | 1638 | §101DP | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18277944 | COMBINATION GENE THERAPY FOR TREATMENT OF METASTATIC CANCER | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103DP | Non-Final OA | — | Pending | Aug 18, 2023 |
| 17438921 | REVERSIBLE COATING OF CHITOSAN-NUCLEIC ACID NANOPARTICLES AND METHODS OF THEIR USE | ROGERS, JAMES WILLIAM | 1618 | §103§112 | Non-Final OA | — | Pending | Sep 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEngene Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Michael D Burkhart has the most, with 1 of Engene Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
